Robotic gloveless isolator technology enhances regional production of advanced therapeutics

To meet growing demands of advanced therapy manufacturing, production architectures must shift towards agile, efficient manufacturing systems. Robotic gloveless isolator (RGI) technology addresses the challenges faced by CDMOs and other manufacturers, particularly in aseptic filling, a critical step in advanced therapy production. By integrating RGI technology into bioproduction, manufacturers can meet the needs of plasmid DNA, viral vector, and mRNA-based medicines while maintaining compliance with stringent regulatory standards.

Please enter your email to access content Read now